Business
Kodiak Sciences Announces Upcoming Presentation of Additional KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2020 Meeting
PALO ALTO, Calif., Feb. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel
About this update from Kodiak Sciences Inc
[{"type":"text","content":"PALO ALTO, Calif., Feb. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that a presentation of additional clinical study data on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2020 meeting being held on February 8, 2020, in Miami, Florida.\n\"We are planning to present new safety, efficacy and durability data on over 400 injections in 130 patients,\" said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. \"Previously, we announced remarkable biological durability and safety of KSI-301 in treatment naïve patients across the three retinal diseases of wet AMD, Diabetic Macular Edema and Retinal Vein Occlusion. The clinical data continue to mature nicely. Later this year we are planning to initiate four additional pivotal clinical studies of KSI-301 with the objective to file an initial BLA in 2022. We look forward to Dr. Do's presentation and to engaging with the community on our data and plans.\"\nDetails of the presentation are as follows:Title: Update on Clinical Studies of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate with Potential for Extended Durability in Wet AMDPresenter: Diana V. Do, M.D., Professor of Ophthalmology at Byers Eye Institute, Stanford University School of Medicine, Stanford, CA Presentation date and time: February 8, 2020; 2:52 PM ET\nKodiak plans to issue a press release relating to the data and to post the slide presentation on the \"Investors & Media\" section of Kodiak's website at http://ir.kodiak.com/ at the beginning of Dr. Do's presentation.\nAbout KSI-301\nKSI-301 is an investigational anti-VEGF therapy built on the Company's Antibody Biopolymer Conjugate, or ABC, Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing agents. Kodiak's objective with KSI-301 is to develop a new first-line agent to improve outcomes for patients with retinal vascular diseases and to enable earlier treatment and prevention of vision loss for patients with diabetic eye disease. The Company's DAZZLE pivotal study in patients with treatment-naïve wet AMD was initiated in October 2019. Kodiak plans to initiate additional pivotal studi...